Monte Rosa Therapeutics, Inc.
As of Oct 22, 2026, Monte Rosa Therapeutics is in Stage 4, the downtrend phase, now in week 7 (since Sep 10, 2026). It closed at $11.11, 56.1% below its 52-week high and below its 200-day average, which is falling.
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively d… More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is GLUE early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
GLUE among Biotechnology145th of 591 by relative strength
All 591 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | GTBP | Stage 2 · wk 7 | 99 | −22.3% |
| 2 | IOVA | Stage 2 · wk 18 | 99 | +38.8% |
| 3 | SLS | Stage 3 · wk 4 | 99 | −1.5% |
| 4 | MRNA | Stage 2 · wk 17 | 99 | +11.3% |
| 5 | TWST | Stage 2 · wk 39 | 99 | −14.5% |
| 6 | KOD | Stage 2 · wk 4 | 99 | +172.1% |
| 7 | ERAS | Stage 3 · wk 5 | 99 | +0.7% |
| 8 | CLYM | Stage 3 · wk 3 | 99 | −15.8% |
| …145 | GLUE | Stage 4 · wk 7 | 67 | −6.6% |
Monte Rosa Therapeutics: quick answers
What stage is Monte Rosa Therapeutics in?
As of Oct 22, 2026, Monte Rosa Therapeutics (GLUE) is in Stage 4, the downtrend phase. It entered Stage 4 on Sep 10, 2026 and is in week 7. What the four stages mean
Is Monte Rosa Therapeutics in an uptrend?
No. Monte Rosa Therapeutics is in a Stage 4 downtrend. It trades 37.5% below its 200-day average, which is falling.
How far is Monte Rosa Therapeutics from its 52-week high?
Monte Rosa Therapeutics closed at $11.11 on Oct 22, 2026, 56.1% below its 52-week high of $25.31. Its 52-week low is $9.35.
How has Monte Rosa Therapeutics performed over the past year?
As of Oct 22, 2026, Monte Rosa Therapeutics is up 15.8% over the past year and down 27.4% so far in 2026.
Which sector and industry is Monte Rosa Therapeutics in?
Monte Rosa Therapeutics is in the Biotechnology industry, part of the Health Care sector.
About this companyHealth Care· Biotechnology
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops orally bioavailable molecular glue degraders (MGDs), such as MRT-2359 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of neurologic and systemic autoimmune and inflammatory diseases; and MRT-8102 for the treatment of inflammatory diseases driven by IL-1a, IL-1ß and IL-18, as well as damage-associated molecular patterns. In addition, it develops CDK2 to treat multiple cancers, including ovarian, endometrial, gastric and breast. Further, its pipeline includes programs in immunology and inflammation indications, oncology, cardiovascular, metabolic, and genetic diseases. The company also develops QuEEN, a discovery engine, to enable its target-centric MGD discovery and development approach and its rational design of MGD product candidates. It has a strategic collaboration and licensing agreement with F. Hoffmann-La Roche Ltd.; and Novartis. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.